AED Quiz | Episode 18 | Audio Epilepsy Digest

1. What is the most defensible meaning of saying that levetiracetam is safe for long-term use? No adverse effect can emerge after the first year. For appropriately selected patients, no characteristic progressive organ-toxicity syndrome is known to accumulate predictably with years of exposure, while behavioral effects, fatigue, rare serious reactions, renal function, and seizure benefit still require reassessment. Its lifetime serious-adverse-event probability is below 1 percent. It is safer than every alternative antiseizure medication.

Correct answer: B. The reassuring long-term profile is not a guarantee of harmlessness or a universal ranking. Ongoing tolerability, susceptibility, dose exposure, and seizure-control benefit remain part of the clinical judgment.

2. Why does exposure beyond seven years in a levetiracetam continuation study not establish a seven-year safety probability for every patient who starts treatment? The study used the wrong antiseizure medication. Maximum exposure is identical to median exposure. The cohort selected prior beneficiaries, follow-up duration varied, and people who discontinued earlier no longer informed the long-duration tail. Open-label follow-up cannot report any adverse events.

Correct answer: C. Long-extension cohorts are useful for detecting what occurred during prolonged exposure, but their late denominators are enriched for people who benefited and tolerated treatment well enough to continue.

3. Which statement best preserves the timing of lamotrigine risk? Serious rash risk is greatest during initiation and titration, but later risk is not literally zero and long-term cohorts are survivor enriched. A patient who reaches eight weeks can never develop a serious rash. Six years of continuation proves lifetime safety. All long-term neurologic adverse effects are caused by rash biology.

Correct answer: A. The defining serious-rash risk is front-loaded and titration sensitive, but duration alone cannot exclude every later event. Continuation cohorts preferentially retain prior tolerators.

4. What patient factor most directly changes the interpretation of lacosamide's long-term safety profile? Whether the patient prefers morning appointments. Cardiac disease, conduction vulnerability, and concomitant conduction-active drugs. The calendar year in which treatment began. Whether an extension study reached eight years for any participant.

Correct answer: B. Dizziness and imbalance are common tolerability issues, while PR-interval and arrhythmia precautions become especially relevant with cardiac disease, conduction vulnerability, and interacting drugs.

How Safe Is Safe? The Long-Term Tradeoffs of Common Anti-Seizure Medications

Learning Objectives

Questions

Reflection

Review Basis